MARKET

BIOA

BIOA

BioAge Labs Inc.
NASDAQ
22.81
+0.65
+2.93%
After Hours: 23.13 +0.32 +1.40% 19:59 07/17 EDT
OPEN
21.36
PREV CLOSE
22.16
HIGH
23.49
LOW
21.36
VOLUME
458.71K
TURNOVER
--
52 WEEK HIGH
25.96
52 WEEK LOW
4.110
MARKET CAP
1.01B
P/E (TTM)
-9.4848
1D
5D
1M
3M
1Y
5Y
1D
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Seeking Alpha · 3h ago
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Barchart · 5d ago
Weekly Report: what happened at BIOA last week (0706-0710)?
Weekly Report · 6d ago
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure
Simply Wall St · 07/10 02:22
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
TipRanks · 07/09 10:06
Weekly Report: what happened at BIOA last week (0629-0703)?
Weekly Report · 07/06 10:28
Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102
Simply Wall St · 07/02 15:27
BioAge Labs principal accounting officer Shane Barton disposes of 62,566 common shares for $1,578,254.20
PUBT · 07/01 20:27
More
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Webull offers BioAge Labs, Inc. stock information, including NASDAQ: BIOA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIOA stock methods without spending real money on the virtual paper trading platform.